TD-139

• CAT Number: I009529
• CAS Number: 1450824-22-2
• Molecular Formula: C26H48N8O2
• Purity: 98%
• Target: galectin-3 inhibitor
• Solubility: Soluble in DMSO
• Storage: 0 - 4 °C for short term, or -20 °C for long term
• InChI: InChI=1S/C28H30F2N6O8S/c29-15-5-1-3-13(7-15)17-9-35(33-31-17)21-23(39)19(11-37)43-27(25(21)41)45-28-26(42)22(24(40)20(12-38)44-28)36-10-18(32-34-36)14-4-2-6-16(30)8-14/h1-10,19-28,37-42H,11-12H2/t19-,20-,21+,22+,23+,24+,25-,26-,27+,28+/m1/s1
• InChIKey: YGIDGBAHDZEYMT-MQFIMZJJSA-N
• SMILES: O[C@H]([C@@H](N1N=NC(C2=CC=CC(F)=C2)=C1)[C@H]([C@@H](CO)O3)O)[C@@H]3S[C@H]4[C@@H]([C@@H](N5N=NC(C6=CC=CC(F)=C6)=C5)[C@H]([C@@H](CO)O4)O)O

TD-139 (CAT: I009529) is a galectin-3 inhibitor that shows potential for the treatment of idiopathic pulmonary fibrosis (IPF). Galectin-3 is a protein involved in the progression of fibrosis, including the excessive accumulation of scar tissue in the lungs seen in IPF. TD-139 works by specifically targeting and inhibiting the activity of galectin-3, which can help prevent or reduce fibrosis in the lungs. By blocking galectin-3, TD-139 may have a therapeutic effect in slowing down or reversing the progression of IPF, offering a potential treatment option for this debilitating lung disease.

Reference

1:Wu SY, Huang JH, Chen WY, Chan YC, Lin CH, Chen YC, Liu FT, Wu-Hsieh BA. Cell Intrinsic Galectin-3 Attenuates Neutrophil ROS-Dependent Killing of Candida by Modulating CR3 Downstream Syk Activation. Front Immunol. 2017 Feb 3;8:48. doi: 10.3389/fimmu.2017.00048. PubMed PMID: 28217127; PubMed Central PMCID: PMC5289966.
2:Saksida T, Nikolic I, Vujicic M, Nilsson UJ, Leffler H, Lukic ML, Stojanovic I, Stosic-Grujicic S. Galectin-3 deficiency protects pancreatic islet cells from cytokine-triggered apoptosis in vitro. J Cell Physiol. 2013 Jul;228(7):1568-76. doi: 10.1002/jcp.24318. PubMed PMID: 23280610.